HuGE Literature Finder
Records
1
-
30
| Uncommon EGFR mutations in lung carcinoma: features and treatment outcomes in a retrospective French cohort. Journal of thoracic disease 2022 Jun 14 (6): 2034-2044. Tankere Pierre, Boidot Romain, Bonniaud Philippe, Zouak Ayoube, Foucher Pascal, Milliere Alice, Bertaut Aurélie, Favier Laure, Lagrange Aurélie, Ghiringhelli François, Kaderbhai Courèche Guillaume, Fraisse Cl |
| Correlation between Programmed Death Ligand-1(PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype. Asian Pacific journal of cancer prevention : APJCP 2022 Jan 23 (1): 131-142. Pandey Rahul Kumar, Shukla Saumya, Husain Nuzhat, Islam Mohammad Hayatul, Hadi Rahat, Kant Tripathi Surya, Singhal Ashi |
| Integration of rapid PCR testing as an adjunct to NGS in diagnostic pathology services within the UK: evidence from a case series of non-squamous, non-small cell lung cancer (NSCLC) patients with follow-up. Journal of clinical pathology 2022 Jan . Finall Alison, Davies Gareth, Jones Trevor, Emlyn Gwion, Huey Pearl, Mullard An |
| Study of Programmed Death Ligand 1 and EGFR/HER2 Expression in Non-Small-Cell Lung Carcinoma With a Clinicopathological Spectrum. Cureus 2021 Jul 13 (7): e16195. Laishram Devina, Raphael Vandana, Marbaniang Evarisalin, Harris Caleb, Jagtap Vikas, Wankhar Baphiraly |
| Use of the Idylla EGFR Mutation Test for Variant Detection in Non-Small Cell Lung Cancer Samples. American journal of clinical pathology 2021 Apr . Hawkins Paul, Stevenson Tracey, Powari Mani |
| Correlation of TTF-1 immunoexpression and EGFR mutation spectrum in non–small cell lung carcinoma. Journal of pathology and translational medicine 2021 07 . Nakra Tripti, Singh Varsha, Nambirajan Aruna, Malik Prabhat Singh, Mohan Anant, Jain Deepa |
| Treatment Patterns and Survival of Patients With Advanced Non-Small Cell Lung Cancer Guided by Comprehensive Genomic Profiling: Real-World Single-Institute Study in China. Frontiers in oncology 2021 11 630717. Lv Weize, Cheng Hua, Shao Di, Wei Yajun, Zhu Weiping, Wu Kui, Jiang Wenxi, Hu Liyang, Sha Zhou, Zhong Beilong, Pei Xiaofe |
| Impact of HER2 expression on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS study subset analysis. Lung cancer (Amsterdam, Netherlands) 2020 Oct 150 83-89. Ohashi Kadoaki, Ninomiya Kiichiro, Yoshioka Hiroshige, Bessho Akihiro, Shibayama Takuo, Aoe Keisuke, Ishikawa Nobuhisa, Kozuki Toshiyuki, Kawai Haruyuki, Kuyama Shoichi, Miyoshi Seigo, Fujitaka Kazunori, Obata Hideto, Tsubata Yukari, Awaya Yoshikazu, Inoue Masaaki, Inoue Koji, Horita Naokatsu, Yanai Hiroyuki, Hotta Katsuyuki, Kiura Katsuyu |
| Lung Cancer in Bahrain: Histological and Molecular Features. The Gulf journal of oncology 2020 Sep 1 (34): 48-51. Mubarak Aalaa, Aljufairi Eman, Almahari Sayed A |
| Management of medically inoperable and tyrosine kinase inhibitor-naïve early-stage lung adenocarcinoma with epidermal growth factor receptor mutations: a retrospective multi-institutional analysis. BMC cancer 2020 Jul 20 (1): 646. Sun Yuemei, Wu Mengwan, Zhou Mingxiu, Luo Xing, Guo Yan, Bai Hansong, Zhang Zican, Tian Wei, Wang Xiaoshan, Bai Yifeng, Zhu Xueqiang, Pan Haixia, Deng Ying, Hu Honglin, Xia Jianling, Hao Xinbao, Han Liangfu, Wei Min, Liu Yingyi, Zeng Mi |
| Detection of Low-level EGFR c.2369 C?>?T (p.Thr790Met) Resistance Mutation in Pre-treatment Non-small Cell Lung Carcinomas Harboring Activating EGFR Mutations and Correlation with Clinical Outcomes. Pathology oncology research : POR 2020 Jun . Ye Linda, Mesbah Ardakani Nima, Thomas Carla, Spilsbury Katrina, Leslie Connull, Amanuel Benhur, Millward Micha |
| Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma. Thoracic cancer 2020 Mar . Kishikawa Takayuki, Kasai Takashi, Okada Masahiko, Nakachi Ichiro, Soda Sayo, Arai Ryo, Takigami Ayako, Sata Masafu |
| Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes. Molecular cancer therapeutics 2019 Jun . Couetoux du Tertre Mathilde, Marques Maud, Tremblay Lise, Bouchard Nicole, Diaconescu Razvan, Blais Normand, Couture Christian, Pelsser Vincent, Wang Hangjun, Higenell Valerie, Izzi Luisa, Gambaro Karen, Hoffert Cyrla, Srivastava Archana, Spatz Alan, Rousseau Caroline, McNamara Suzan, Cohen Victor, Batist Gerald, Agulnik Jas |
| EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer. BMC cancer 2019 Jun 19 (1): 595. Fang Wenfeng, Huang Yihua, Hong Shaodong, Zhang Zhonghan, Wang Minghui, Gan Jiadi, Wang Wenjing, Guo Honglin, Wang Kai, Zhang |
| A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2. Cancer research and treatment : official journal of Korean Cancer Association 2019 Apr 51 (2): 777-787. Park Cheol-Kyu, Cho Hyun-Ju, Choi Yoo-Duk, Oh In-Jae, Kim Young-Ch |
| A study of therapy targeted EGFR/ALK mutations in Indian patients with lung adenocarcinoma: A clinical and epidemiological study. Medical journal, Armed Forces India 2018 Apr 74 (2): 148-153. Rana Vandana, Ranjan Praveer, Jagani Rajat, Rathi K R, Kumar Dharmesh, Khera Anur |
| Mutation abundance affects the therapeutic efficacy of EGFR-TKI in patients with advanced lung adenocarcinoma: A retrospective analysis. Cancer biology & therapy 2018 Mar 1-35. Wang Huijuan, Zhang Mina, Tang Wanyu, Ma Jie, Wei Bing, Niu Yuanyuan, Zhang Guowei, Li Peng, Yan Xiangtao, Ma Zhiyo |
| Frequency of Somatic TP53 Mutations in Combination with Known Pathogenic Mutations in Colon Adenocarcinoma, Non-Small Cell Lung Carcinoma, and Gliomas as Identified by Next-Generation Sequencing. Neoplasia (New York, N.Y.) 2018 Feb 20 (3): 256-262. Shajani-Yi Zahra, de Abreu Francine B, Peterson Jason D, Tsongalis Gregory |
| KRAS mutation is predictive of outcome in patients with pulmonary sarcomatoid carcinoma. Histopathology 2018 Feb . Mehrad Mitra, Roy Somak, LaFramboise William A, Petrosko Patti, Miller Caitlyn, Incharoen Pimpin, Dacic San |
| Uncommon frame-shift exon 19 EGFR mutations are sensitive to EGFR tyrosine kinase inhibitors in non-small cell lung carcinoma. Medical oncology (Northwood, London, England) 2018 Jan 35 (3): 28. Improta Giuseppina, Zupa Angela, Natalicchio Maria Iole, Sisinni Lorenza, Marinaccio Anna, Bozza Giovanni, Vita Giulia, Aieta Michele, Landriscina Matt |
| RASA1 and NF1 are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Non-Small Cell Lung Carcinomas Sensitive to MEK Inhibition. Clinical cancer research : an official journal of the American Association for Cancer Research 2017 Nov . Hayashi Takuo, Desmeules Patrice, Smith Roger S, Drilon Alexander, Somwar Romel, Ladanyi Ma |
| [Clinical significance and mechanism of upregulation of PI3Kp110a in non-small cell lung carcinoma]. Zhonghua zhong liu za zhi [Chinese journal of oncology] 2017 Oct 39 (10): 737-743. Xiong Y, Qu L L, Li D, Wang Y, Li |
| Correlation between molecular analysis, diagnosis according to the 2015 WHO classification of unresected lung tumours and TTF1 expression in small biopsies and cytology specimens from 344 non-small cell lung carcinoma patients. Pathology 2017 Aug . Russell Prudence A, Rogers Toni-Maree, Solomon Benjamin, Alam Naveed, Barnett Stephen A, Rathi Vivek, Williams Richard A, Wright Gavin M, Conron Matth |
| Relationship between driver gene mutations, their relative protein expressions and survival in non-small cell lung carcinoma in Macao. The clinical respiratory journal 2017 Jul . Chan Kin Iong, Vong Hong Ting, Sin Lai Fang, Yip Yuk Ching, Zhong Xue Yun, Wen Jian Mi |
| Low plasma concentration of gefitinib in patients with EGFR exon 21 L858R point mutations shortens progression-free survival. Cancer chemotherapy and pharmacology 2017 Apr . Okuda Yuji, Sato Kazuhiro, Sudo Kazuhisa, Hasegawa Yukiyasu, Asano Mariko, Miura Hajime, Takeda Masahide, Sano Masaaki, Watanabe Hiroyuki, Kobayashi Hiroyuki, Niioka Takenori, Miura Masatomo, Ito Hiros |
| Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs. PloS one 2017 12 (3): e0173524. Zhang Chengjuan, Wei Bing, Li Peng, Yang Ke, Wang Zhizhong, Ma Jie, Guo Yongj |
| Prognostic value of rare and complex mutations in EGFR and serum levels of soluble EGFR and its ligands in non-small cell lung carcinoma patients. Clinical biochemistry 2016 Dec . Haghgoo Seyyed Mortaza, Khosravi Adnan, Mortaz Esmaeil, Pourabdollah-Toutkaboni Mihan, Seifi Sharareh, Sabour Siamak, Allameh Abdolam |
| A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A. Lung cancer (Amsterdam, Netherlands) 2016 Sep 99 131-6. Usui Kazuhiro, Sugawara Shunichi, Nishitsuji Masaru, Fujita Yuka, Inoue Akira, Mouri Atsuto, Watanabe Hiroshi, Sakai Hiroshi, Kinoshita Ichiro, Ohhara Yoshihito, Maemondo Makoto, Kagamu Hiroshi, Hagiwara Koichi, Kobayashi Kunihiko, |
| Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma. Oncotarget 2016 Jul . Rachiglio Anna Maria, Abate Riziero Esposito, Sacco Alessandra, Pasquale Raffaella, Fenizia Francesca, Lambiase Matilde, Morabito Alessandro, Montanino Agnese, Rocco Gaetano, Romano Carmen, Nappi Anna, Iaffaioli R Vincenzo, Tatangelo Fabiana, Botti Gerardo, Ciardiello Fortunato, Maiello Monica R, De Luca Antonella, Normanno Nico |
| Association between survivin genetic polymorphisms and epidermal growth factor receptor mutation in non-small-cell lung cancer. International journal of medical sciences 2016 13 (12): 929-935. Liu Tu-Chen, Hsieh Ming-Ju, Wu Wen-Jun, Chou Ying-Erh, Chiang Whei-Ling, Yang Shun-Fa, Su Shih-Chi, Tsao Thomas Chang-Y |
- Page last reviewed:Jul 25, 2022
- Page last updated:Aug 09, 2022
- Content source: